Abstract
The article presents the regional experience of organizing immunoprophylaxis of respiratory 
 syncytial viral infection in premature infants, including those with bronchopulmonary dysplasia, with palivi zumab is presented on the basis of Regional Children's Clinical Hospital named after. N.N. Silischeva. In the 
 follow-up of children who received this drug for the observation period from 2019 to 2021, the following were 
 noted: the absence of side effects and undesirable effects of the drug, high adherence of parents to treatment 
 with palivizumab, the advantages of a centralized approach to organizing the prevention of RSV infection in 
 premature infants from the high-risk group in the Astrakhan region.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
